Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia

Authors: Linyu Yang, Qiang Qiu, Minghai Tang, Fang Wang, Yuyao Yi, Dongni Yi, Zhuang Yang, Zejiang Zhu, Shoujun Zheng, Jianhong Yang, Heying Pei, Li Zheng, Yong Chen, Liping Gou, Liya Luo, Xing Deng, Haoyu Ye, Yiguo Hu, Ting Niu, Lijuan Chen

Published: 2019-08-22

DOI: 10.1158/1078-0432.ccr-19-0516

Source: Full article

Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>–Induced B-Cell Acute Lymphoblastic Leukemia

Abstract